BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 28, 2026
Breaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld

BioWorld
BioWorld RSS Feed RSS

J&J buying Halda for $3.05B; new anti-resistance cancer approach

Nov. 17, 2025
No Comments
A preview of the next edition of BioWorld, Nov. 17, 2025
Read More

Biggest gainers and losers for Nov. 10-14, 2025

Nov. 17, 2025
The top 10 biopharma stock gainers and losers for the week.
Read More

ICYMI: Week in review, Nov. 10-14, 2025

Nov. 17, 2025
A quick look back at top stories.
Read More
Abstract illustration of pig and human with medical motifs
Nephrology

‘Encyclopedia’ of xenotransplantation reveals drivers of immune rejection

Nov. 17, 2025
By Anette Breindl
No Comments
By transplanting a pig kidney into a brain-dead person, researchers have been able to conduct the first long-term study of the physiological processes occurring in both the transplant recipient and the pig organ for 61 days. The findings were published in the Nov. 14, 2025, issue of Nature in two papers – one focusing on physiological and immunological measurements, the other on multiomics.
Read More

Money raised by biopharma

Nov. 14, 2025
Total raised in public, private and other financings of biopharma companies, comparing 2019-2025.
Read More

Biopharma money raised: Jan. 1-Nov. 13, 2025

Nov. 14, 2025
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Other news to note for Nov. 14, 2025

Nov. 14, 2025
Biopharma happenings, including deals and partnerships, and other news in brief: Century, Charm, Daiichi, Day One, Decoy, Flightpath, General Proximity, Kaken, Mersana, Metsera, Novo Nordisk, Numab, Pfizer, Salarius, Sarepta.
Read More

In the clinic for Nov. 14, 2025

Nov. 14, 2025
Clinical updates, including data readouts and publications: Enterome, Gilead, Neurogene, Novartis.
Read More

Financings for Nov. 14, 2025

Nov. 14, 2025
Biopharmas raising money in public or private financings, including: 4Teen4, Aeon, Annexon, Daewoong, Engene, Inventiva, Ionis, Nurexone, Palatin, Scripta, T-Therapeutics, Virometix.
Read More

Appointments and advancements for Nov. 14, 2025

Nov. 14, 2025
New hires and promotions in the biopharma industry, including: Blue Cell, Imu, Neurvati, Prime, RBL, Sentinel.
Read More
Previous 1 2 … 247 248 249 250 251 252 253 254 255 … 9169 9170 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 28, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • Drug capsule spilling onto brain

    Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

    BioWorld Science
    Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
  • EMA logo on mobile screen, vials, syringes

    Daybu readthrough in EU? Zevra’s NPC bid flounders

    BioWorld
    Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
  • Business pipeline illustration

    Transcripta Bio raises funding to advance neuro pipeline

    BioWorld Science
    Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing